Lilly(Eli) & Co
LLY
Market Cap$708.78B
Close$
Earnings Call Q4 2023
February 6, 2024 - AI Summary
Revenue in Q4 2023 grew by 28% compared to the same period in 2022, driven by new product launches and growth products.
Key pipeline milestones were achieved, including positive Phase III results for Tirzepatide and Verzenio, as well as positive Phase II results for Orforglipron and Retatrutide.
Several acquisitions and collaborations were completed to enhance the pipeline, including the acquisition of POINT Biopharma and the entry into radioligand therapy.
Exclusive for Stockcircle Pro members
Sign up
$258.69
64.3% downside
Current Fair Value
64.3% downsideOvervalued by 64.3% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $708.78 Billion |
|---|---|
| Enterprise Value | $731.07 Billion |
| Dividend Yield | $4.6775 (0.63%) |
| Earnings per Share | $5.8 |
| Beta | 0.63 |
| Outstanding Shares | 950,164,452 |
| Avg 30 Day Volume | 2,382,371 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 135.25 |
|---|---|
| PEG | 1039.99 |
| Price to Sales | 20.71 |
| Price to Book Ratio | 65.9 |
| Enterprise Value to Revenue | 21.42 |
| Enterprise Value to EBIT | 70.8 |
| Enterprise Value to Net Income | 139 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 2.34 |
Revenue Sources
No data
ESG Score
No data
About Lilly(Eli) & Co
CEO: David Ricks